Imatinib Mesylate

Rediff.com » News » Imatinib Mesylate

News for Imatinib Mesylate

Business

Natco opposes Novartis patent claim

Natco Pharma has opposed an application made by Novartis India to the controller of patents, for grant of a patent for an anti-cancer drug 'Imatinib Mesylate'. The company has filed a pre-grant......

8 anti-cancer drugs to be categorised as essential

Eight commonly prescribed anti-cancer drugs will soon enter India's National List of Essential Medicines (NLEM).The entry assumes significance in the backdrop of a Supreme Court directive to the......

Novartis gets patent for cancer drug

Swiss drug manufacturer Novartis AG has been granted patent protection in India for Nilotinib, a superior version of blood cancer drug Gleevec (imatinib mesylate). It has been engaged in a legal......

HC rejects Novartis' plea on patent

The Madras High Court on Monday dismissed a petition filed by Swiss pharmaceutical major Novartis AG, challenging the constitutional validity of the section 3 (d) of the Patents (Amendment) Act......

Novartis denied patent for cancer drug

The Patent Controller Office of India has rejected the patent application of Novartis AG for its cancer drug Gleevec.Assistant Controller of Patents & Designs V Rengasamy rejected the application......

Imatinib Mesylate

News for Imatinib Mesylate

Natco opposes Novartis patent claim

8 anti-cancer drugs to be categorised as essential

Novartis gets patent for cancer drug

HC rejects Novartis' plea on patent

Novartis denied patent for cancer drug

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS